IQ-AI Limited shares latest progress from Phase I glioblastoma clinical trial
IQ-AI Limited shares latest progress from Phase I glioblastoma clinical trial
–News Direct–
Dr Jennifer Connelly, the Principal Investigator (PI) of the IQ-AI Limited sponsored Phase I Clinical Trial that is being conducted at the Medical College of Wisconsin, joins Proactive's Natalie Stoberman to discuss the latest updates from its treatment for recurring glioblastoma patients.
IQ-AI Ltd, the parent company of Wisconsin-based Imaging Biometrics, LLC (IB), is focused on delivering quantitative imaging platforms and therapeutics that transform how clinicians diagnose and treat patients more efficiently and effectively.
Contact Details
Proactive Investors
+1 347-449-0879
na-editorial@proactiveinvestors.com
View source version on newsdirect.com: https://newsdirect.com/news/iq-ai-limited-shares-latest-progress-from-phase-i-glioblastoma-clinical-trial-206132431
IQ-AI Ltd
COMTEX_437041890/2655/2023-07-19T13:03:04
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No DigiShor journalist was involved in the writing and production of this article.
© 2017 VictorThemes - Elite Themeforest Author.